JNCE Jounce Therapeutics Inc.

15.14
+0.10  (1%)
Previous Close 15.04
Open 15.12
Price To book 2.79
Market Cap 488200837
Shares 32,245,762
Volume 18,283
Short Ratio 19.33
Av. Daily Volume 181,924

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171194254
  2. 8-K - Current report 171193081
  3. 8-K - Current report 171148295
  4. SC 13G - Statement of acquisition of beneficial ownership by individuals 171111527
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171016823

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial initiated September 2017.Phase 2 arm initiation announced April 21, 2017. Efficacy data due 1H 2018.
JTX-2011
Solid tumors - Cancer

Latest News

  1. Can This Tiny Biotech Stock Pay Off Big for Celgene?
  2. Jounce Therapeutics Reports Third Quarter 2017 Financial Results
  3. Jounce Therapeutics to Present at the Stifel 2017 Healthcare Conference
  4. Jounce Therapeutics to Announce Third Quarter 2017 Financial Results and Host Conference Call on Monday, November 13, 2017
  5. Jounce Therapeutics to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
  6. Jounce Therapeutics Appoints Luis A. Diaz, Jr., M.D., to its Board of Directors
  7. Jounce Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JNCE-US : October 19, 2017
  8. Jounce Therapeutics to Present at Upcoming Investor Conferences in September
  9. Jounce Therapeutics, Inc. – Value Analysis (NASDAQ:JNCE) : August 29, 2017
  10. Jounce Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JNCE-US : August 18, 2017
  11. Jounce Therapeutics (JNCE) Jumps: Stock Moves 7.4% Higher
  12. Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
  13. 3 Top Healthcare Stocks You Haven't Thought Of
  14. OncoSec Announces Technology Access Program Agreement with Jounce Therapeutics, Inc.
  15. Jounce Therapeutics, Inc. – Value Analysis (NASDAQ:JNCE) : May 19, 2017
  16. Jounce Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JNCE-US : May 18, 2017

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171194254
  2. 8-K - Current report 171193081
  3. 8-K - Current report 171148295
  4. SC 13G - Statement of acquisition of beneficial ownership by individuals 171111527
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171016823
  6. 8-K - Current report 171016415
  7. 8-K - Current report 17863103
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 17825686
  9. 8-K - Current report 17824747
  10. 8-K - Current report 17773158